Concord Biotech's Q1 FY 2025-26 Quarterly Results
- 09 Aug 2025
Result Summary
- Concord Biotech Ltd reported a 34.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 3.7%.
- Its expenses for the quarter were down by 19.3% QoQ and up 8.4% YoY.
- The net profit decreased 53.6% QoQ and decreased 26.1% YoY.
- The earnings per share (EPS) of Concord Biotech Ltd stood at 4.2 during Q1 FY 2025-26.
Financial Statments for Q1 FY 2025-26
| (₹ crores) | Q1FY26 | Q4FY25 | Q1FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 217.67 | 329.78 | 226.11 | -34.0% | -3.7% |
Total Expenses | 160.43 | 198.86 | 147.94 | -19.3% | 8.4% |
Profit Before Tax | 57.24 | 130.92 | 78.17 | -56.3% | -26.8% |
Tax | 14.67 | 33.70 | 19.93 | -56.5% | -26.4% |
Profit After Tax | 44.06 | 95.02 | 59.59 | -53.6% | -26.1% |
Earnings Per Share | 4.20 | 9.10 | 5.70 | -53.8% | -26.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Concord Biotech Ltd is an established player in the biotechnology industry, primarily focusing on the development and manufacturing of active pharmaceutical ingredients (APIs) and finished formulations within the field of biosimilars. The company's operations are crucial in supporting the pharmaceutical and healthcare sectors, with a broad range of products that cater to various therapeutic areas. As of the data available, there are no specific recent major developments reported for Concord Biotech Ltd. This analysis is based on the financial data pertaining to the quarter ending in the first quarter of fiscal year 2026.
Revenue
Concord Biotech Ltd's total income for the first quarter of fiscal year 2026 was ₹217.67 crores. This represents a decline of 34.0% on a quarter-over-quarter (QoQ) basis from ₹329.78 crores in the previous quarter (Q4FY25). When compared to the same quarter in the previous year (Q1FY25), there is a slight decrease of 3.7% from ₹226.11 crores. These figures highlight the fluctuations in revenue within the periods analyzed, with a notable drop in the most recent quarter compared to the previous quarter.
Profitability
The company's profit before tax for Q1FY26 stood at ₹57.24 crores, marking a significant decrease of 56.3% QoQ from ₹130.92 crores in Q4FY25. On a year-over-year (YoY) basis, profit before tax also decreased by 26.8% from ₹78.17 crores in Q1FY25. Concord Biotech Ltd reported a profit after tax of ₹44.06 crores in Q1FY26, which is a 53.6% decline QoQ from ₹95.02 crores in the previous quarter and a 26.1% decrease YoY from ₹59.59 crores in Q1FY25. The earnings per share (EPS) for Q1FY26 was ₹4.20, down by 53.8% QoQ from ₹9.10 in Q4FY25 and down 26.3% YoY from ₹5.70 in Q1FY25. These metrics indicate fluctuations in profitability across the quarters and highlight the changes compared to the previous year.
Operating Metrics
In terms of operating metrics, total expenses for Concord Biotech Ltd in Q1FY26 amounted to ₹160.43 crores. This is a decrease of 19.3% QoQ from ₹198.86 crores in Q4FY25, but an increase of 8.4% YoY from ₹147.94 crores in Q1FY25. The taxation for Q1FY26 was ₹14.67 crores, showing a decline of 56.5% QoQ from ₹33.70 crores in the previous quarter and a decrease of 26.4% YoY from ₹19.93 crores in the same quarter last year. These figures offer insights into the company's cost management and tax obligations over the periods in question.
FAQs
When was Concord Biotech Ltd Q1 FY 2025-26 result announced?
Concord Biotech Ltd announced its Q1 FY 2025-26 results on 9 August, 2025.
What are Concord Biotech Ltd quarterly results?
Concord Biotech Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
What were the key highlights of Concord Biotech Ltd Q1 FY 2025-26 results?
Key highlights of Concord Biotech Ltd Q1 FY 2025-26 results include:
- Revenue: ₹217.67 crore
- Net Profit: ₹44.06 crore
- EBITDA: ₹75.07 crore
- Year-over-Year Growth: -3.7%
- Quarter-over-Quarter Growth: -34.0%
How did Concord Biotech Ltd net profit perform in this quarter?
Concord Biotech Ltd reported a net loss of ₹44.06 crore in Q1 FY 2025-26, reflecting a -26.1% year-over-year growth.
What was Concord Biotech Ltd revenue in Q1 FY 2025-26?
Concord Biotech Ltd posted a revenue of ₹217.67 crore in Q1 FY 2025-26.